EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined Synucleinopathy

Daniel Weintraub iD, Michele K York, Roseanne Dobkin, Anuprita R Nair, Ryan Kurth, David-Erick Lafontant, Chelsea Caspell-Garcia, Roy N Alcalay, Ethan G Brown iD, Lana M Chahine, Christopher Coffey, Tatiana Foroud und 13 weitere

Annals of Clinical and Translational Neurology · 2026-11 · 13 (11) · 2323-2335

DOI: 10.1002/acn3.70399 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 21.04.2026. Verfasst von Daniel Weintraub und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurology, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: REM Sleep Behavior Disorder, Prodromal Symptoms, Lewy Body Disease, Synucleinopathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker‐defined synucleinopathy.

Methods

Parkinson's Progression Markers Initiative (PPMI) is a longitudinal, multi‐center observational study. Participants included polysomnogram (PSG)‐confirmed iRBD individuals who were cerebrospinal fluid (CSF) α‐synuclein seed amplification assay positive with no clinical diagnosis of Parkinson's disease or dementia with Lewy bodies, along with robust healthy controls (HCs). Clinical and biological features of prodromal PD and DLB, including mild cognitive impairment (MCI), subthreshold parkinsonism, and a range of neuropsychiatric, autonomic, and sensory symptoms, were assessed.

Results

Compared with HCs ( N = 136), iRBD participants ( N = 197) demonstrated worse cognitive performance, including a lower cognitive summary score ( p < 0.0003, effect size = 0.41), and higher odds of subthreshold parkinsonism (OR = 24.5), and neuropsychiatric (OR = 3.5), autonomic (OR = 7.2) and sensory symptoms (OR = 13.2). Common features included hyposmia (75%), pain (54%), urinary problems (52%), constipation (49%), lightheadedness (40%) and anxiety (36%), whereas rates of MCI (32%), subthreshold parkinsonism (27%) and psychosis (7%) were lower. iRBD participants with abnormal dopamine transporter imaging had higher anxiety scores and antidepressant use. Although only 10% met criteria for prodromal DLB due to the requirement for MCI, most exhibited multi‐domain impairment. Interpretation iRBD with synucleinopathy is associated with multi‐domain clinical impairment before clinical neurodegenerative disease diagnosis, supporting broad clinical assessment in early biomarker‐defined synuclein disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

REM Sleep Behavior DisorderProdromal SymptomsLewy Body DiseaseSynucleinopathiesalpha-SynucleinCognitive DysfunctionParkinson DiseaseHumansFemaleMaleAgedBiomarkersMiddle AgedLongitudinal StudiesPolysomnographyDisease Progression

Stichwörter der Autor:innen

RBDautonomicdementiamild cognitive impairmentneuropsychiatric

Substanzen

Biomarkersalpha-Synuclein

Autor:innen und Institutionen

  • Department of Psychiatry and Neurology, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Psychiatry, Rutgers University, New Brunswick, New Jersey, USA.
  • Department of Biostatistics, University of Iowa, Iowa City, Iowa, USA.
  • Movement Disorders Division, Tel Aviv Sourasky Medical Center; Tel Aviv, Israel, Columbia University Irving Medical Center, New York, New York, USA.
  • Department of Neurology, University of California San Francisco, San Francisco, California, USA.

ORCID-Profile: Daniel Weintraub, Ethan G Brown, Kathleen L Poston, Tanya Simuni

Förderung

  • Michael J. Fox Foundation for Parkinson's Research

Zitieren

APA

Weintraub, D., York, M. K., Dobkin, R., Nair, A. R., Kurth, R., Lafontant, D. E., Caspell-Garcia, C., Alcalay, R. N., Brown, E. G., Chahine, L. M., Coffey, C., Foroud, T., Galasko, D., Kieburtz, K., Marek, K., Merchant, K., Mollenhauer, B., Poston, K. L., Siderowf, A., …, & Parkinson's Progression Markers Initiative (2026). Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined Synucleinopathy. Annals of Clinical and Translational Neurology, 13(11), 2323-2335. https://doi.org/10.1002/acn3.70399

Vancouver

Weintraub D, York MK, Dobkin R, Nair AR, Kurth R, Lafontant DE, et al. Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined Synucleinopathy. Annals of Clinical and Translational Neurology. 2026;13(11):2323-2335. doi:10.1002/acn3.70399

BibTeX
@article{Weintraub2026,
  author = {Weintraub, Daniel and York, Michele K and Dobkin, Roseanne and Nair, Anuprita R and Kurth, Ryan and Lafontant, David-Erick and Caspell-Garcia, Chelsea and Alcalay, Roy N and Brown, Ethan G and Chahine, Lana M and Coffey, Christopher and Foroud, Tatiana and Galasko, Douglas and Kieburtz, Karl and Marek, Kenneth and Merchant, Kalpana and Mollenhauer, Brit and Poston, Kathleen L and Siderowf, Andrew and Simonet, Cristina and Simuni, Tanya and Tanner, Caroline M and Tropea, Thomas F and Videnovic, Aleksandar and Parkinson's Progression Markers Initiative, Parkinson's Progression Markers Initiative},
  title = {Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined Synucleinopathy},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {11},
  pages = {2323--2335},
  doi = {10.1002/acn3.70399}
}
Kostenlos starten →